SUMMARY Proton beam irradiation has been used for the treatment of 6() eyes with choroidal melanomas located 3 mm or less from the fovea. The average follow-up period was 18 months. 86% of the treated lesions showed regression at the time of this analysis, and the 14% that did not were followed up for less than a year. Visual acuity remained the same in 47% of the treated eyes, improved in 20%, and deteriorated in 33%. 58%/n of the treated eyes had visual acuity of 20/100 or better at the last follow-up examination. Radiation vasculopathy with macular oedema was the most common complication, and it was observed in 22%'/ of the treated eyes. These preliminary observations suggest that proton beam irradiation may be a reasonable alternative to enucleation even for this group of choroidal melanomas, which is considered unfavourable in respect of the preservation of visual function. treatment. We have therefore advised our patients that a tumour-free area at least 3 mm (2 disc diameters) from the fovea was required for preservation of central vision, since only with such a margin could the dose to the fovea be kept below 50% of the tumour dose. There was no serious expectation of preservation of central vision when lesions were located closer than 3 mm from the fovea. This has proved not to be uniformly true. We report here on the current status of those patients we have treated whose tumours were closer than 3 mm to or involved the macula.
Proton beam irradiation has been used for the treatment of uveal melanomas at the Harvard cyclotron since 1975, and 260 patients have been treated so far. Early results have shown that proton beam therapy has increased the number of tumours that can be treated conservatively and has decreased the incidence of ocular morbidity and treatment failure associated with other conservative methods.' These accomplishments of proton radiotherapy are based exclusively on the physical characteristics of protons which make possible highly localised dose distributions.2 With protons a uniform dose can be delivered throughout the tumour with minimal irradiation to the surrounding tissues. In particular, the lateral sharpness which can be provided with proton beams allows irradiation of tumours located quite posteriorly and close to the macula or the optic nerve. Our usual treatment technique provides a 15 mm margin between the visible tumour and the 90% isodose contour, to allow for microscopic extension of the lesion, positional error, and motion during the !-Plr-cscntcd at thc M'actila Socicty Mcct;nig. Orlando Flor-idal 4 March 1983.
Corrcspondcncc to Evangclos S. Grai-goudas. MD treatment. We have therefore advised our patients that a tumour-free area at least 3 mm (2 disc diameters) from the fovea was required for preservation of central vision, since only with such a margin could the dose to the fovea be kept below 50% of the tumour dose. There was no serious expectation of preservation of central vision when lesions were located closer than 3 mm from the fovea. This has proved not to be uniformly true. We report here on the current status of those patients we have treated whose tumours were closer than 3 mm to or involved the macula.
Subjects and methods
From 1975 to the end of 1982 we examined 60 patients with a choroidal melanoma closer than 3 mm to or involving the fovea, who were then treated with proton beam irradiation at the Harvard cyclotron. We have reported previously on the pretreatment evaluation and the technical aspects of the operative technique for the localisation of the tumour, the treatment planning, and the techniques of proton irradiation. The The distribution of the tumours according to their location and size is shown in Table 2 . Twenty-nine (48%) of the melanomas were large, 26 (43%) were of medium size, and only 5 eyes had small tumours. In 14 eyes (23%) the fovea was involved, in 25 (42%) the distance of the tumour from the fovea was less than 1 DD and in 21 (35%) 1 to 2 DD. The relationship Preliminary results ofproton beacm irraidiation ofmaccular andparamacular melanomas between size of the tumour and distance from the fovea was not statistically significant. The length of follow-up in these patients ranged from 2 months to 82 months, with an average of 18 months (Table 3) . For purposes of analysis the followup period was broken into two intervals: 'short' in 32 patients who were followed up less than a year, and 'long' in 28 patients observed for longer than one year.
Results
We observed disappearance ofthe lesion or formation of a flat scar in 11 eyes (Fig. 1) . Forty-one of the 1ig. IU tumours decreased in size, and the 8 that remained stable were in patients who were followed up for less than a year at the time of this analysis.
VISUAL ACUITY
The pretreatment and most recent postirradiation visual acuities of the treated eyes in relation to the location of the tumour are shown in Fig. 3 . The level of visual acuity remained the same in 28 (47%) eyes, improved in 12 (20%), and deteriorated in 20 (33%). In eyes with tumours involving the fovea the visual 
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Discussion
The superior dose distributions provided by protons or helium ions4 offer two major clinical advantages in the field of ocular radiotherapy. First they can treat larger tumours than the radiotherapeutic plaques, because the irradiated volume is reduced, and therefore the tolerance of the eye is substantially increased. The second important clinical advantage is the ability to treat lesions close to critical structures like the macula and the optic nerve. In these locations the sharp reduction of dose outside the target volume with the use of protons permits the delivery of potentially tumoricidal doses to the lesion with sparing of the vital and radiosensitive nearby normal structures. In addition the Bragg peak, which is characteristic of heavy charged particles such as protons, allows a very uniform dose distribution throughout the tumour and the margin of normal tissue around the lesion which is included for adequate coverage of the melanoma borders. This cannot be achieved with radioactive 'plaques, which deliver extraordinarily high doses (up to 450000 rads) to the base of the tumour and quite substantial doses to the surrounding tissues.5
In this study we have attempted to assess the effect of proton irradiation on visual acuity in eyes with tumours closer than 3 mm to, or involving, the fovea. Although there was no serious expectation of preservation of central vision in these eyes in the initial stages of our studies, our preliminary results are rather optimistic. Twenty-four (40%) of the treated eyes had a last visual acuity of 20/40 or better and 35 (58%) of 20/100 or better. Apart from the four eyes in diabetic patients, in which diabetes probably compounded the radiation injury, direct radiation injury to the macula was not the cause ofmarkedly decreased vision (worse than 20/200).
Complications like vitreous haemorrhage, cataract, and retinal detachment or destruction of the photoreceptors by the tumour before irradiation, in cases where the fovea was involved, were responsible for the visual deficit. It is difficult to tell with certainty whether the visual loss is secondary to vascular changes or to the direct effect of radiation on retinal cells, but the data from this study favour the former.
In almost all cases the decreased vision could be explained by the observed retinal vascular complications.
It is possible that some maculae can tolerate our present radiation dose schedule without direct retinal cellular damage from irradiation. There were four patients in the second location category and three in the third who were followed up for more than two years after irradiation and whose most recent visual acuity was 20/40 or better. One patient with a melanoma less than I DD from the fovea who has been followed up for seven years after irradiation of the macula to 50 CGY still maintains 20/40 visual acuity. Recent observations of eyes treated with the cobalt plaques suggest that the lowest dose for inducing foveal damage is 10000 rads." Although the nature or quality of the radiation, the volume irradiated, and the fractionation scheme used are quite different in the two forms of treatment, making direct comparison difficult, it is worth noting that the ability to deliver a homogeneous dose with protons makes it possible to achieve a very high probability of sterilisation of the tumour with less than 10 000 rads.
The size of the tumour is an important determinant of post-treatment visual acuity. Macular oedema was observed twice as often in eyes with large melanomas as in eyes having medium size tumours. Visual acuity improved in 14% and deteriorated in 45% of eyes with large tumours compared with 31% improvement and 27% deterioration in eyes with medium size tumours.
Diabetes mellitus seems to have a sensitizing effect on the radiation damage of retinal vessels. All four patients with diabetes developed marked vascular changes from radiation even in eyes without diabetic retinopathy. Postirradiation retinopathy is a form of retinal vascular occlusive disorder7 " very similar to diabetic retinopathy, and the retinal vessels in these patients are more prone to occlusion and leakage. Neovascularisation of the retina developed in one of these eyes and was treated successfully with laser photocoagulation.
Radiation vasculopathy and macular oedema have been observed as early as four months and as late as four years after irradiation (average 10 months) in this study. However, in other studies postirradiation retinopathy has been observed as late as 15 years afterwards,"' and we could observe more vascular complications in the future. A multivariate analysis is needed to determine the independent effect of multiple variables on visual acuity outcome. These include tumour size, distance from the fovea, radiation dose to the macula, presence of retinal detachment involving the fovea, and follow-up time. Such an analysis will be done when the sample is larger. Nevertheless, our preliminary observations which we report here make us believe that proton beam irradiation is a reasonable alternative to enucleation for paramacular or macular melanomas. 67% of the eyes treated retained the same vision or improved, and 58% had visual acuity of 20/100 or better at the time of this analysis. Central vision of the treated eyes is not lost, at least for the follow-up period of this study in the majority of the cases, and some can retain very good vision years after irradiation.
